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Appropriate Use Criteria to
Reduce Underuse and Overuse
Striking the Right Balance*
Manesh R. Patel, MD
Durham, North Carolina
“We are what we repeatedly do.
Excellence is not an act, but a habit.”
Aristotle (1)
Each physician caring for patients with obstructive coronary
artery disease attempts daily to determine the patient’s
individualized risk for future cardiovascular events, the
patient’s symptom burden, and then provide recommenda-
tions on therapies aimed at improving the symptom/
functional status of the patient and reducing the risk of
cardiovascular events. Inherent in this complex decision-
making process is the physician’s evaluation and application
of the available evidence to the specific patient with subse-
quent shared decision making with patients’ wishes. For
stable ischemic heart disease, these decisions often revolve
around revascularization with either percutaneous coronary
intervention (PCI) or coronary artery bypass grafting
(CABG).
See page 1876
Recently, concerns over utilization, mainly around over-
use, have led to significant changes in the review and process
for payment for cardiovascular procedures in general, and
PCI specifically. In this context, the American College of
Cardiology developed and recently updated appropriate use
criteria (AUC) for coronary revascularization (2) in an effort
to provide structure and inform revascularization decisions
and to understand current patterns of care. However, the
AUC for coronary revascularization have been met with
important critiques, particularly questions about the out-
comes of patients by AUC criteria, terminology, and pos-
sible underutilization.
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important step in the evaluation and improvement of the
AUC in clinical practice. The authors perform a retrospec-
tive review of over 1,628 patients with stable coronary artery
disease undergoing cardiac catheterization between April
2006 and March 2007, from a representative sample of all
angiograms performed in the province of Ontario, Canada,
during the study period. The authors had trained nurse
abstractors review the charts to determine the appropriate-
ness score of all the patients, both those undergoing
revascularization and those treated medically, with 3-year
follow-up for death or acute coronary syndrome (ACS).
The nurse abstractors focused on the 4 key variables for
AUC: 1) clinical presentation and symptom severity; 2)
intensity of anti-ischemic medical therapy; 3) ischemic
burden as determined by noninvasive testing; and 4) extent
of coronary stenosis on coronary angiography. Several of the
findings from the study represent important answers to
questions around AUC.
The investigators found that 14% of coronary revascular-
ization procedures (18% for PCI) were classified as inap-
propriate in this population of patients with stable coronary
artery disease. This rate from the Canadian population is
similar to the 12% rate for elective stable angina PCI
observed in the larger observational study from the National
Cardiovascular Data Registry in the United States (4). As
previously noted by many, the rate of revascularization proce-
dures classified as inappropriate should not be expected to be
zero, as there are a myriad of clinical features and exceptions
that are not accounted for by the limited scenarios for coronary
revascularization. These rates do start to provide benchmarks
so the providers and institutions can review practice patterns,
and highlight indications and clinical areas that need better
clarity in future AUC documents.
However, the most important finding from the analysis
by Ko et al. (3) does not revolve around inappropriate
coronary revascularization. Rather, the investigators de-
scribe important findings around the potential underuse of
coronary revascularization. They found that only 69% of
patients with an appropriate indication for coronary revas-
cularization underwent revascularization (57% with PCI
and 43% with CABG), and the patients who underwent
revascularization had a significantly lower risk of death or
repeat ACS at 3 years (hazard ratio [HR]: 0.61; 95%
confidence interval [CI]: 0.42 to 0.88) compared with
similarly classified patients who were treated medically, even
after adjustment for baseline variables. This reduction in
clinical events was not seen in patients with a revasculariza-
tion classification of uncertain (HR: 0.57; 95% CI: 0.28 to
1.16) or inappropriate (HR: 0.99; 95% CI: 0.48 to 2.02).
The study is limited by its retrospective nature, and
therefore the inability to fully account for and control
unmeasured confounders may affect the decision to perform
coronary revascularization. Additionally, the investigators
do not have any information on quality of life, symptom, or
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benefits in the patients. Nevertheless, the study provides a
large, well-conducted analysis that demonstrates through
the use of the published AUC for coronary revascularization
that there are likely patients where coronary revasculariza-
tion is underused, in addition to previously described
concerns about overuse. As with the inappropriate classified
procedures, it is important to note that the appropriate
classification does not mean that revascularization is man-
dated or that a 100% rate would be expected. Rather this
classification highlights patients at the highest risk for
coronary artery disease. Additionally, the investigators
found a gradient with adverse clinical outcomes across the
AUC categories. So what do these findings mean to
clinicians, patients, and policy makers in the era of health-
care reform, and how can they be reconciled with prior
studies?
Hemingway et al. (5) previously described the underuse
of coronary revascularization and the associated adverse
clinical outcomes. This was an important observation in the
percutaneous transluminal coronary angioplasty era, which
included both stable and ACS patients. The current analysis
goes the next step and provides a real-world contemporary
analysis of stable coronary artery disease patients without
prior CABG or PCI in the preceding year. The findings are
also in line with the evolving consensus toward ischemia-
driven revascularization (6).
Review of these features of the real-world patients de-
scribed helps possibly explain why patients categorized as
appropriate for revascularization might have improved clinical
outcomes when considered in context of the COURAGE (Clin-
ical Outcomes Utilizing Revascularization and Aggressive
Drug Evaluation) trial (7). As noted by the authors, some
patients in the current analysis may have been excluded from
COURAGE due to significant left main stenosis or 3-vessel
disease, high-risk stress test findings, or other high-risk
features. The majority of these patients with high-risk
features would be categorized as appropriate for revascular-
ization and likely represents the patients with the largest
possible benefit from revascularization. In fact, review of the
spectrum of patients in each revascularization strata (appro-
priate, uncertain, and inappropriate) demonstrates that the
patients at highest risk (and potentially at highest likelihood
of benefit) do not always get coronary revascularization,
another example of the “risk-treatment paradox” in the
practice of medicine.
Furthermore, as more studies with invasive hemodynamic
lesion assessment, such as fractional flow reserve, demon-
strate clinical benefit (8), the science behind what improves
patient outcomes is becoming clearer. So how do clinicians,
patients, and health systems put processes in place that
provide the most efficient care of patients with stable
coronary artery disease, a process that increases the use of
revascularization in patients that may benefit the greatest,
and reduce procedures where the benefit may be much less
to nonexistent?The first step requires a framework for thinking about all
cardiac procedures, including coronary revascularization
(Fig. 1). In this framework, the initial decision to perform a
procedure (right patient–right procedure) is made on the
basis of clinical guidelines and in large part to AUC. Here
the available evidence is discussed in the context of these
criteria and guidelines so that patients can make informed
and shared decisions. It should be noted that medical
therapy alone without revascularization is a decision for
which the side effects, risks, and possible benefits have to be
discussed. Patients can then make their choices (prefer-
ences) known.
For patients undergoing coronary revascularization, a
checklist that includes the AUC and is used at the timeout
before the procedure should be considered. Research with
surgery has shown that a simple safety checklist, which
includes ensuring the team is aware of patient confirmation,
expected risks, and possible complications, reduces mortality
(9). Once the procedure is started, the remaining aspects of
quality then include performing the procedure in the right
way (effected by ongoing clinical trial evidence), and obtain-
ing the right or expected clinical outcomes (quality metrics
and possible public reporting). This framework, if electron-
ically captured in real time with decision support, will
hopefully inform clinicians and allow our patients and our
society to evaluate the care of the patients with stable
coronary artery disease. It is with this type of learning
network that physicians will obtain timely feedback and the
AUC will obtain real-world patient data, so that definitions
and criteria can be continuously improved.
Unfortunately, the current infrastructure and ongoing
actions with healthcare reform do not support the robust
collection of data for understanding practice patterns, but
simply the implementation of mechanisms to control ser-
vices such as prior authorization. These mechanisms are
inherently flawed because patients who are not getting
services that might be essential or beneficial are not re-
viewed or previously authorized. Rather, payers should
consider systems that allow shared risk and gains with
providers that implement efficient care processes without
the current control mechanisms. It should be noted that the
decision process for care of patients with ischemic heart
disease starts well before the catheterization laboratory, and
tools to provide support in electronic health records are not
Figure 1 Framework for High-Quality
Cardiovascular Procedurespresent in the current clinical environment.
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with other stakeholders, should continue to encourage
innovation and ensure systems are put into place to inform
patients and physicians about coronary revascularization.
Ideally, real-time clinical decision support tools with out-
puts that include AUC and patient-specific risk scores
would be embedded in portable electronic health records
that eventually become parts of the structured reports at the
end of the revascularization procedure. In the interim,
simple paper and web checklists should be used. The current
study highlights the need for these types of tools to help
guide the use of revascularization, reduce the risk-treatment
paradox, and improve patient outcomes. It is with these
types of tools that cardiovascular physicians can continue to
have the discipline and daily habits to ensure efficient and
excellence in cardiac care.
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